This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Impax Laboratories Inc (IPXL)

NASDAQ: Health Care

$31.95 -0.37 | -1.14%
11/28/14 - 1:00 PM ET
  • Prev Close: 32.32
  • Day's Open: 32.47
  • Volume: 202.62K
  • Avg Vol: 599.50K
  • Shares Outstanding: 71.25M
  • Mkt Cap: 2.30B
  • Div: --
  • Div Yield: --
  • P/E: 48.97
  • EPS: 1.51
IPXL Day's Range
$31.88
$32.92
IPXL 52 Week Range
$21.34
$32.35
IPXL Business Summary
Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products; and develops and markets branded products. The company operates through two segments, Global Pharmaceuticals Division and Impax Pharmaceutical Division.View IPXL key stats
IPXL Performance as of Prev. Close
YTD
28.56%
3-Mo
29.75%
1-Yr
37.65%
3-Yr
84.58%
IPXL EPS Performance
1-Yr Ago
1.51
2-Yrs Ago
0.85
3-Yrs Ago
1.02
IPXL Percentage in these ETFs
0.040%
0.024%
0.023%
0.012%
0.004%
IPXL News

IPXL Impax Laboratories Inc

Analysts Ratings for IPXL

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 0 1 1 1
Moderate Buy 1 1 0 0
Hold 6 5 5 5
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
GET IPXL ANALYST REPORT

Brokerage Partners

IPXL Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs